GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tenax Therapeutics Inc (FRA:YBO0) » Definitions » YoY EPS Growth

Tenax Therapeutics (FRA:YBO0) YoY EPS Growth : 74.60% (As of Mar. 2024)


View and export this data going back to 2008. Start your Free Trial

What is Tenax Therapeutics YoY EPS Growth?

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. Tenax Therapeutics's YoY EPS Growth for the quarter that ended in Mar. 2024 was 74.60%.

Tenax Therapeutics's Earnings per Share (Diluted) for the three months ended in Mar. 2024 was €-2.87.

Tenax Therapeutics YoY EPS Growth Historical Data

The historical data trend for Tenax Therapeutics's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tenax Therapeutics YoY EPS Growth Chart

Tenax Therapeutics Annual Data
Trend Apr14 Apr15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
YoY EPS Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 63.49 34.76 -78.84 74.62 94.98

Tenax Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
YoY EPS Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 92.80 97.85 96.66 83.45 74.60

Tenax Therapeutics YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

Tenax Therapeutics's YoY EPS Growth for the fiscal year that ended in Dec. 2023 is calculated as:

YoY EPS Growth (A: Dec. 2023 )
=(Earnings per Share (Diluted) (A: Dec. 2023 )-Earnings per Share (Diluted) (A: Dec. 2022 ))/ | Earnings per Share (Diluted) (A: Dec. 2022 ) |
=(-28.464--567.07)/ | -567.07 |
=94.98 %

Tenax Therapeutics's YoY EPS Growth for the quarter that ended in Mar. 2024 is calculated as:

YoY EPS Growth (Q: Mar. 2024 )
=(Earnings per Share (Diluted) (Q: Mar. 2024 )-Earnings per Share (Diluted) (Q: Mar. 2023 )) / | Earnings per Share (Diluted) (Q: Mar. 2023 )) |
=(-2.87--11.301)/ | -11.301 |
=74.60 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tenax Therapeutics YoY EPS Growth Related Terms

Thank you for viewing the detailed overview of Tenax Therapeutics's YoY EPS Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Tenax Therapeutics (FRA:YBO0) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tenax Therapeutics Inc (FRA:YBO0) » Definitions » YoY EPS Growth
Comparable Companies
PULM TFFP PTIX SCPX LGVN ENTO KTTA CVKD NTBL SIGY OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB BNTX XBRU:ARGX
Traded in Other Exchanges
TENX:USA
Address
101 Glen Lennox Drive, Suite 300, Chapel Hill, NC, USA, 27517
Website
https://www.tenaxthera.com
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of Pulmonary Hypertension associated with Heart Failure and preserved Ejection Fraction.

Tenax Therapeutics (FRA:YBO0) Headlines

No Headlines